The European Society for Medical Oncology (ESMO) Annual Congress was held from 27 September to 1 October 2019 in Barcelona, Spain. Continue reading
More than 3.900 abstracts have been submitted to the European Society for Medical Oncology Congress (ESMO) Annual Congress which will be held from 27 September to 1st October 2019 in Barcelona, Spain. Continue reading
More than 3.900 abstracts have been submitted to the European Society for Medical Oncology Congress (ESMO) Annual Congress which will be held from 27 September to 1st October 2019 in Barcelona, Spain. Continue reading
Led by International Myeloma Society (IMS), the 17th International Myeloma Workshop (IMW) will be held in Boston, USA, from 12 to 15 September. During the Workshop the latest breakthroughs in myeloma and related diseases will be presented and analysed by leading doctors, researchers and patient advocates in the community. Continue reading
European Commission (EC) has approved elotuzumab –marketed under the brand Empliciti by Bristol-Myers Squibb (BMS)– plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy. Continue reading
DREAMM-2, the pivotal open-label, randomised study of two doses of belantamab mafodotin has reported a clinically meaningful overall response rate (ORR) in relapsed myeloma patients. Continue reading
With the aim of addressing common educational needs of the cancer advocacy community, the Workgroup of European Cancer Patient Advocacy Networks (WECAN) held the first WECAN Academy from 6-9 July 2019 in Frankfurt, Germany. Continue reading
MMPredict is a HORIZON 2020 project, which Myeloma Patients Europe (MPE) is involved in, aimed at clinically validating a personalised medicines tool that predicts the most effective treatment options for myeloma patients.
As part of MMPredict, MPE has been involved in the development and dissemination of a survey assessing the quality of life of European myeloma patients, particularly relating to currently available myeloma treatments and how side-effects impact upon them. Continue reading
The pharmaceutical company Janssen, who produce a range of myeloma medicines, have today announced their application to the European Medicines Agency (EMA) for a license extension for daratumumab. This license extension, if approved by the EMA, would allow the use of subcutaneous (under the skin) daratumumab (Darzalex®) in myeloma patients. Continue reading
The first WECAN Academy organised by the Workgroup of European Cancer Patient Advocacy Networks (WECAN) will take place 6-9 July 2019 in Frankfurt, Germany. This training programme is aimed at growing the knowledge and skills of more than 100 European leading patient advocates, and those who joined the community more recently, in the areas of: Continue reading